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The oral administration of Lacticaseibacillus rhamnosusCRL1505 differentially modulates
the respiratory innate antiviral immune response triggered by Toll-like receptor 3 (TLR3)
activation in infant mice, improving the resistance to Respiratory Syncytial Virus (RSV)
infection. In this work, by using macrophages depletion experiments and a detailed
study of their production of cytokines and antiviral factors we clearly demonstrated
the key role of this immune cell population in the improvement of both viral elimination
and the protection against lung tissue damage induced by the CRL1505 strain. Orally
administered L. rhamnosus CRL1505 activated alveolar macrophages and enhanced
their ability to produce type I interferons (IFNs) and IFN-γ in response to RSV infection.
Moreover, an increased expression of IFNAR1, Mx2, OAS1, OAS2, RNAseL, and IFITM3
was observed in alveolar macrophages after the oral treatment with L. rhamnosus
CRL1505, which was consistent with the enhanced RSV clearance. The depletion of
alveolar macrophages by the time of L. rhamnosus CRL1505 administration abolished
the ability of infant mice to produce increased levels of IL-10 in response to RSV infection.
However, no improvement in IL-10 production was observed when primary cultures of
alveolar macrophages obtained from CRL1505-treated mice were analyzed. Of note,
alveolar macrophages from the CRL1505 group had an increased production of IL-6 and
IL-27 suggesting that these cells may play an important role in limiting inflammation and
protecting lung function during RSV infection, by increasing the maturation and activation
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of Treg cells and their subsequent production of IL-10. In addition, we provided evidence
of the important role of CD4+ cells and IFN-γ in the activation of alveolar macrophages
highlighting a putative pathway through which the intestinal and respiratory mucosa are
communicated under the influence of L. rhamnosus CRL1505.
Keywords: Lacticaseibacillus rhamnosus CRL1505, immunobiotics, TLR3, viral immunity, Respiratory Syncytial
Virus, alveolar macrophages
INTRODUCTION
The effect of the intestinal microbiota on the immune responses
in the respiratory tract and its impact on the outcome of
viral infections has been explored during the last decade
(1–3). Those studies demonstrated that the signals provided by
the intestinal microbiota act at multiple levels in the respiratory
mucosa stimulating an antiviral state in non-immune cells and
innate immune cells that would allow an efficient control of
viral replication early during the infection. Although these effects
of the intestinal microbiota have been documented mainly for
Influenza Virus (IFV) infection (1–3), it should be considered
that the cellular and molecular mechanisms involved in the
innate antiviral immune response are not virus specific and
therefore, they are similar for all the respiratory viruses. Then, the
beneficial microbes in the intestinal tract may favorably influence
the innate immune responses to other respiratory viruses as
well. In this regard, it was recently demonstrated that a high-
fiber diet improved the production of acetate by the intestinal
microbiota of mice and that this metabolic product modulated
the activity of respiratory interferon (IFN)-β and increased the
expression of interferon-stimulated genes (ISGs) in the lung (4).
The immunological changes induced in the respiratory tract by
the dietary treatment significantly increased the resistance of
mice to the challenge with Respiratory Syncytial Virus (RSV).
The studies with germ-free as well as antibiotic-treated
mice recolonized with bacteria demonstrated that the changes
induced by the intestinal microbiota in the respiratory antiviral
immune response are reversible and more importantly, tunable
(1–3, 5). Moreover, it was shown that not all commensal bacteria
could contribute equally to the antiviral immunocompetence
in the lung (1). These findings have opened the possibility
of exploring particular strains of beneficial bacteria with
immunomodulatory capacities, referred to as immunobiotics, in
order to increase antiviral defenses in the respiratory tract. Then,
several immunomodulatory beneficial microbial strains mainly
from the Lactobacillus and Bifidobacterium species; have been
Abbreviations: BAL, Broncho-alveolar lavages; CXCL1, Chemokine (C-X-C
motif) ligand 1; CLP, Clodronate-containing liposomes; DMEM, Dulbecco’s
modified Eagle’s medium; ELISA, Enzyme-linked immunosorbent assay; ELP,
Empty liposomes; HRP, Horseradish peroxidase; IFV, Influenza Virus; IL,
Interleukin; IFN, Interferon; IFNAR1, IFN-alpha/beta receptor alpha chain;
Mx, IFN-induced GTP-binding protein Mx; ISGs, Interferon-stimulated genes;
IFITM3, IFN-induced transmembrane protein 3; LDH, Lactate dehydrogenase;
MRS, Man-Rogosa-Sharpe; MAMPs, Microbial-associated molecular patterns;
MOI,Multiplicity of infection; OAS, 2’-5’-oligoadenylate synthetase; PRRs, Pattern
recognition receptors; PBS, Phosphate buffer saline; RSV, Respiratory syncytial
virus; RNAseL, Ribonuclease L; TLR3, Toll-like receptor 3.
tested in their capacities to modulate the respiratory antiviral
immune response when orally administered (6, 7). A growing
number of studies have examined the effect of immunobiotic
nutritional interventions on the incidence, the duration and
severity of respiratory infections in humans. Several clinical
trials, systematic reviews and meta-analyses have suggested that
immunobiotics may be effective in improving the resistance
of children against viral respiratory infections such as the
common cold and influenza-like symptoms (8, 9). Interestingly,
immunobiotic intervention was shown to reduce the episodes
of viral respiratory infections even in asthmatic children (10).
Collectively, research has shown that some immunobiotic strains
are capable of making a difference in the host’s response to
respiratory viral infections. However, there is limited information
regarding the cellular and molecular mechanisms involved in
the beneficial effects of each particular immunobiotic strain.
Those kind of studies are necessary to provide solid scientific
basis to promote the use of immunobiotics in the prevention of
respiratory viral infections.
In a randomized controlled trial in children, it was
demonstrated that the immunobiotic strain Lacticaseibacillus
rhamnosus CRL1505 (Basonym, Lactobacillus rhamnosus
CRL1505) (11), administered in a yogurt, improved mucosal
immunity and reduced the incidence and severity of viral
intestinal and respiratory infections (12). Since this finding in
children, our laboratory had perform studies by using in vivo
and in vitro models to characterize the antiviral properties
of L. rhamnosus CRL1505. We demonstrated that the oral
administration of the CRL1505 strain was capable of improving
the resistance of infant mice to RSV infection (13, 14). We
found that L. rhamnosus CRL1505 differentially regulated the
respiratory innate antiviral immune response triggered by
the activation of Toll-like receptor 3 (TLR3), improving the
resistance to RSV infection. The study of the immunological
mechanisms involved in the protective effect induced by L.
rhamnosus CRL1505 revealed a key role for respiratory IFN-
β, IFN-γ, and interleukin (IL)-10. Our results showed that
the increase of the three cytokines in the respiratory tract
induced by the oral CRL1505 treatment was involved in the
reduction of lung RSV titers and inflammatory-mediated
lung tissue injury. Moreover, our studies provided us with
preliminary information that indicate that CD11c+SiglecF+
alveolar macrophages would actively participate in the
beneficial effects induced by L. rhamnosus CRL1505 (13, 14).
However, the exact role of resident alveolar macrophages in the
immunomodulatory effects of the CRL1505 strain have not been
investigated in detail.
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Considering this background, in this work we aimed to further
advance in the characterization of the beneficial effects of L.
rhamnosus CRL1505 in the context of respiratory RSV infection
by evaluating whether their immunomodulatory properties are
dependent on alveolarmacrophages function. The role of alveolar
macrophages in the differential cytokine profile induced in the
respiratory tract by orally administered L. rhamnosus CRL1505,




Lacticaseibacillus rhamnosus CRL1505 and Lactiplantibacillus
plantarum CRL1506 (Basonym, Lactobacillus plantarum
CRL1505) (11) were obtained from the CERELA culture
collection (Chacabuco 145, San Miguel de Tucumán, Argentina).
Both lactobacilli cultures were kept freeze-dried. Lactobacilli
were cultured for 12 h at 37◦C (final log phase) in Man-Rogosa-
Sharpe broth (MRS, Oxoid). The bacteria were harvested by
centrifugation at 3,000 g for 10min, washed three times with
sterile 0.01 mol/L phosphate buffer saline (PBS, pH 7.2), and
resuspended in sterile 10% non-fat milk.
Animals and Treatments
Infant (3-week-old) BALB/c mice were obtained from the closed
colony kept at CERELA (San Miguel de Tucumán, Argentina).
Animals were housed in plastic cages at room temperature and
the assays for each parameter studied were performed in 5–6mice
per group for each time point. Three groups of mice were used:
CRL1505- and CRL1506-treated mice and PBS-treated controls.
L. rhamnosus CRL1505 and L. plantarum CRL1506 strains were
orally administered to infant mice for five consecutive days. Mice
were deprived of water for 4 h and the immunobiotic strains
were given at a dose of 108 cells/mouse/day in a minimum
volume of drinking water containing 10% of non-fat milk to
animals in individual cages (13, 14). The treated groups and
the PBS-treated control group were fed a conventional balanced
diet ad libitum.
This study was carried out in strict accordance with
the recommendations in the Guide for the Care and
Use of Laboratory Animals of the Guidelines for Animal
Experimentation of CERELA. The CERELA Institutional
Animal Care and Use Committee prospectively approved this
research under the protocol BIOT-CRL-18. All efforts were made
to minimize the number of animals and their suffering. No
signs of discomfort or pain were observed before mice reached
the endpoints. No deaths were observed before mice reached
the endpoints.
Blood and respiratory tissue samples were obtained frommice
after the intraperitoneal injection of ketamine (80 mg/kg) and
xylazine (10 mg/kg) according to the recommendations of the
CERELA Institutional Animal Care and Use Committee.
Poly(I:C) Administration and RSV Infection
Administration of the TLR3 agonist poly(I:C) (Sigma-Aldrich)
was performed 2 days after the last day of lactobacilli treatments.
Mice received 100 µl of PBS containing 250 µg poly(I:C)
(equivalent to 10 mg/kg body weight), that was administered
dropwise, via the nares (13, 15, 16). Control animals received 100
µl of PBS. Mice received three doses of poly (I:C) or PBS with
24 h rest period between each administration.
Human RSV strain A2 was grown in Vero cells as described
previously (13–15). Briefly, Vero cells were grown in Dulbecco’s
modified Eagle’s medium (DMEM) and infected with RSV
at a multiplicity of infection (MOI) of 1 in 5ml for 3 h at
37◦C, 5% CO2. After infection, 7ml of DMEM with 10%
fetal bovine serum (Sigma, Tokyo, Japan), 0.1% penicillin-
streptomycin (Pen/Strep) (Sigma, Tokyo, Japan), and 0.001%
ciprofloxacin (Bayer) was added to the flask, and cells were
incubated until extensive syncytium formation was detected.
Then, Vero cells were scraped, sonicated and cell debris was
removed by centrifugation at 700 g for 10min at 4◦C. Virus
supernatant was sucrose density gradient purified and stored
in 30% sucrose at −80◦C. For in vivo infection, mice were
challenged with 106 PFU (Plaque forming units) of RSV by
the nasal route (13–15). Viral challenge was performed 2 days
after the last day of lactobacilli treatments. Lung RSV titers
and tissue damage were evaluated 2 days after viral infection.
The RSV immunoplaque assay was performed as described
previously (14–16), briefly lungs were homogenized and diluted
tissue clarified supernatants were added to Vero cells monolayers.
Samples were run in triplicate. After 3 h of incubation (37◦C,
5% CO2) supernatants were removed and fresh medium
(DMEM, 10% FBS, 0.1% Pen- Strep, 0.001% ciprofloxacin)
was added. Monolayers were fixed with ice cold acetone:
methanol (60:40) when extensive syncytia were observed.
Primary RSV anti-F (clones 131-2A; Chemicon), anti-G (Mouse
monoclonal [8C5 (9B6)] to RSV glycoprotein, Abcam) and
secondary horseradish peroxidase anti-mouse immunoglobulin
(Anti-mouse IgG, HRP-linked Antibody #7076, Cell signaling
Technology) antibodies were used. Individual plaques were
developed using a DAB substrate kit (ab64238, Abcam)
following manufacture’s specifications. Results were expressed as
log10 PFU/g of lung.
Lung Injury Parameters
Broncho-alveolar lavages (BAL) samples were obtained as
described previously (16, 17). Briefly, the trachea was exposed
and intubated with a catheter, and 2 sequential lavages were
performed in each mouse by injecting sterile PBS. The recovered
fluid was centrifuged for 10min at 900 g; and frozen at−70◦C for
subsequent analyses.
Albumin content, a measure to quantitate increased
permeability of the bronchoalveolar–capillarity barrier, and
lactate dehydrogenase (LDH) activity, an indicator of general
cytotoxicity, were determined in the acellular BAL fluid.
Albumin content was determined colorimetrically based
on albumin binding to bromcresol green using an albumin
diagnostic kit (Wiener Lab, Buenos Aires, Argentina). LDH
activity, expressed as units per liter of BAL fluid, was determined
by measuring the formation of the reduced form of nicotinamide
adenine dinucleotide (NAD) using the Wiener reagents and
procedures (Wiener Lab).
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In vivo Depletion of Alveolar Macrophages
For depletion of alveolar macrophages, mice were inoculated
intranasally with 50 µl of clodronate (dichloromethylene-
bisphosphonate)-containing liposomes (CLP; Clophosome,
Stratech, United Kingdom) as described elsewhere (18).
Mice were treated with CLP for two consecutive days.
Optimal conditions of alveolar macrophages depletion
were determined by differential counting of BAL cells
(Figure 1). An equal treatment with empty liposomes (ELP)
served as controls.
The total number of leukocytes and differential cell counts
in BAL samples were performed as described previously
(13, 15, 16). Briefly, the total number of leukocytes was
determined with a hemocytometer. Differential cell counts were
performed by counting 200 cells in blood smears stained with
May Grunwald-Giemsa.
Alveolar Macrophages Primary Cultures
Primary cultures of murine alveolar macrophages was performed
as described elsewhere (19, 20). Macrophages were obtained
from infant mice via bronchoalveolar lavages by using 1ml of
warm sterile PBS containing 5mM EDTA. Macrophages were
transferred to new sterile tubes, washed twice in sterile PBS,
and resuspended in RPMI 1640 medium with 10% FBS, 1mM
L-glutamine, and 100 U/ml penicillin-streptomycin. BAL cells
were seeded in 24-well-plates at a density of 105 cells/well and
incubated for 2 h at 37◦C in 5%CO2 to promote adherence. Non-
adherent cells were washed and macrophages were maintained
in culture in RPMI 1640 medium with 10% FBS, 1mM L-
glutamine, and 100 U/ml penicillin-streptomycin at 37◦C in
5% CO2 for 24 h before stimulation. Alveolar macrophages
were stimulated with poly(I:C) (50 ug/ml), or RSV (MOI of
5). Supernatants were collected before (basal conditions) and
24 h after stimulations, for cytokines analysis. In addition, the
mRNA was extracted from alveolar macrophages 12 h after RSV
challenge for the evaluation of cytokines and antiviral factors
gene expressions.
Cytokine Concentrations in BAL and
Culture Supernatants
BAL samples were obtained as described previously (16, 17).
The samples were frozen at −70◦C for subsequent cytokine
analyses. IFN-β (Mouse IFN-beta ELISA Kit, sensitivity: 15.5
pg/ml), IFN-γ (Mouse IFN-gamma Quantikine ELISA Kit,
sensitivity: 2 pg/ml), IL-6 (Mouse IL-6 Quantikine ELISA Kit,
sensitivity: 1.8 pg/ml), IL-10 (Mouse IL-10 Quantikine ELISA
Kit, sensitivity: 5.2 pg/ml), IL-12 (Mouse IL-12 p70 DuoSet
ELISA, sensitivity: 1.5 pg/ml) and IL-27 (Mouse IL-27 p28/IL-
30 Quantikine ELISA Kit, sensitivity: 4.7 pg/ml), IL-17 (Mouse
IL-17 Quantikine ELISA Kit, sensitivity 5 pg/ml), and the
IL-8 mouse homolog chemokine KC or chemokine (C-X-C
motif) ligand 1 (Mouse CXCL1/KC DuoSet ELISA, sensitivity
2.3 pg/ml) concentrations in BAL and culture supernatants
samples were measured with commercially available enzyme-
linked immunosorbent assay (ELISA) technique kits following
the manufacturer’s recommendations (R&D Systems, MN, USA).
Quantitative Expression Analysis by
Real-Time PCR
Alveolar macrophages were obtained as described above and
total RNA was isolated from each sample using TRIzol reagent
(Invitrogen) according to the manufacturer’s instructions. After
the chloroform step, the aqueous phase–containing RNA was
further processed using the RNeasy Micro kit (QIAGEN)
according to the manufacturer’s instructions.
Two-step real-time quantitative PCR was performed to
characterize the expression of IFN-α, IFN-β, IFN-γ , IFN-
alpha/beta receptor alpha chain (IFNAR1), IFN-λ1, IFN-λ2/3,
the IFN-induced GTP-binding protein Mx1 (Mx1), Mx2, the 2′-
5′-oligoadenylate synthetase 1 (OAS1), OAS2, the ribonuclease
L (RNAseL), and the IFN-induced transmembrane protein 3
(IFITM3) genes in cultured alveolar macrophages. All cDNAs
were synthesized using a Quantitect reverse transcription (RT)
kit (Qiagen, Tokyo, Japan) according to the manufacturer’s
recommendations. Real-time quantitative PCR was carried out
using a 7300 real-time PCR system (Applied Biosystems,
Warrington, United Kingdom) and the Platinum SYBR green
qPCR SuperMix uracil-DNA glycosylase (UDG) with 6-carboxyl-
X-rhodamine (ROX) (Invitrogen). The primers used in this work
are given in the (Supplementary Table 1). The PCR cycling
conditions were 2min at 50◦C, followed by 2min at 95◦C, and
then 40 cycles of 15 s at 95◦C, 30 s at 60◦C, and 30 s at 72◦C.
The reaction mixtures contained 5 µl of sample cDNA and 15 µl
of master mix, which included the sense and antisense primers.
Expression of β-actin was used to normalize cDNA levels for
differences in total cDNA levels in the samples.
Flow Cytometry Analysis
Single cells from BAL samples were prepared as previously
described (14, 16, 17). Erythrocytes were depleted by
hypotonic lysis and the cells were washed with RPMI medium
supplemented with 10% heat-inactivated fetal calf serum (FCS).
Cells were counted using Trypan Blue exclusion and then
resuspended at an appropriate concentration of 5× 106 cells/ml.
BAL cell suspensions were pre-incubated with anti-mouse
CD32/CD16 monoclonal antibody (Fc block) for 15min at
4◦C. Cells were incubated in the antibody mixes for 30min at
4◦C and washed with FACS buffer. Then, cells were stained
with fluorochrome-conjugated antibodies against CD11c (APC),
SiglecF (PE) (BD Bioscience), CD45 (FITC) (eBioscience),
and MHC-II (PerCP) (Thermo Fisher Scientific). Cells were
then acquired on a BD FACSCaliburTM flow cytometer (BD
Biosciences) and data were analyzed with FlowJo software
(TreeStar). The total number of cells in each population was
determined by multiplying the percentages of subsets within a
series of marker negative or positive gates by the total cell number
determined for each BAL sample (14, 16, 17).
Blocking Experiments
In order to evaluate the role of IFN-γ in the immunomodulatory
capacity L. rhamnosus CRL1505, anti-IFN-γ blocking antibodies
were used. Different groups of mice were orally treated with
L. rhamnosus CRL1505 for 5 consecutive days at a dose of
108 cells/mouse/day as described above. On days 1, 3, and
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FIGURE 1 | Effect of alveolar macrophages depletion on the ability of Lacticaseibacillus rhamnosus CRL1505 to modulate the respiratory immune response triggered
by poly(I:C) treatment. Infant mice were nasally treated with clodronate-containing liposomes (CLP) during 2 days (days 0 and 1) to induce the depletion of alveolar
macrophages. One day after the last CPL administration mice were orally treated with L. rhamnosus CRL1505 or Lactiplantibacillus plantarum CRL1506 (108
cell/mouse/day) during five consecutive days (days 2–6) and challenged with three once-daily doses of poly(I:C) (days 8, 9, and 10). Mice treated with empty
liposomes (ELP), CRL1505 or CRL1506 and then challenged with poly(I:C) were used as controls. Two days after the last poly(I:C) administration lactate
dehydrogenase (LDH) activity, albumin concentrations, and the levels of interferon (IFN)-β, IFN-γ, and interleukin (IL)-10 in broncho-alveolar lavages (BAL) were
evaluated. The results represent data from three independent experiments. Asterisks indicate significant differences between the respective ELP and CLP groups.
Asterisks in black lines indicate significant differences between the indicated groups. *P < 0.05, **P < 0.01.
5 mice were injected intraperitoneally with 20 ug of purified
anti-IFN-γ antibodies (LEAFTM Purified anti-mouse IFN-γ IgG1
antibody, #505706 BioLegend) or 80 ug of isotype control
antibodies (LEAFTM Purified Rat IgG1, % Isotype Ctrl, LEAFTM
Purified Rat IgG1, % Isotype Ctrl, BioLegend) as we described
previously (13). For CD4 depletion, mice were intraperitoneally
injected with 200 µg of anti-α-CD4 antibodies (Rat IgG2b, clone
GK1.5; #AB1107636, BioXcell) or IgG isotype control antibodies
(rat IgG2b isotype, clone LTF-2, #BE0090, BioXcell) on
days 1, 3, and 5.
Statistical Analysis
Experiments were performed in triplicate and results were
expressed as mean ± standard deviation (SD). After verification
of the normal distribution of data, 2-way ANOVA was used.
Tukey’s test (for pairwise comparisons of the means) was used
to test for differences between the groups. Differences were
considered significant at p < 0.05.
RESULTS
Effect of Alveolar Macrophages Depletion
on the Capacity of L. rhamnosus CRL1505
to Modulate the Respiratory Immune
Response Triggered by Poly(I:C)
The nasal administration of liposomes containing
toxic substances such as clodronate is a widely used
technic to evaluate the role of alveolar macrophages in
respiratory immune responses (18, 20). Here, we used
this experimental approach to evaluate the role of alveolar
macrophages in the immunomodulatory effects of orally
administered L. rhamnosus CRL1505. In addition, we
used the immunobiotic strain L. plantarum CRL1506 for
comparison. Our previous studies demonstrated that the
oral administration of the CRL1505 or CRL1506 strains to
mice are able to beneficially modulate intestinal antiviral
immunity (21, 22). However, only L. rhamnosus CRL1505
exerts a beneficial effect at a distance by modulating
respiratory immunity.
In our hands, the nasal administration of clodronate-
containing liposomes (CLP) significantly reduced the number
of macrophages in BAL samples for a period of 6 days. The
number of BAL macrophages started to recover from day 7
(Figure 1). This effect was not observed in infant mice nasally
treated with empty liposomes (ELP) in which BAL macrophages
numbers were normal during all the assessed period. These
results indicated that CLP treatment is useful for evaluating
the role of alveolar macrophages in the immunomodulatory
effect of the CRL1505 strain in our experimental models, since
these immune cells are decreased at the time of lactobacilli
administration, while their number return to normality when the
poly(I:C) or RSV challenges occur.
We and others demonstrated that the nasal administration
of the TLR3 agonist poly(IC) to mice induce an inflammatory
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response and lung functional changes that are similar to
those caused by RSV (13, 14). Therefore, we used the nasal
administration of the dsRNA analog poly(I:C) to mimic the
pro-inflammatory and physiopathological consecuences of RNA
viral infections in the lung. In addition, we used the BAL
biochemical markers albumin and LDH to assess the lung
damage. Albumin is not detected normally in BAL samples
and the increase of this protein in the respiratory tract is an
indicator of an increased permeability of the bronchoalveolar–
capillarity barrier. On the other hand, the increase of the
intracellular enzyme LDH in BAL samples is an indicator
of cytotoxicity (13, 14).
It was observed that in infant mice treated with
ELP and challenged with poly(I:C) the levels of BAL
LDH and albumin increased significantly after TLR3
activation (Figure 1). It was also observed that in
animals treated with ELP and L. rhamnosus CRL1505
and subsequently challenged with poly(I:C) the levels
of BAL LDH and albumin were significantly lower than
those found in their respective control group (ELP
control mice) (Figure 1). These results clearly indicate
that treatment with ELP does not modify the number or
functionality of alveolar macrophages, since both the effect
of poly(I:C) and the CRL1505 strain in ELP-treated mice
are similar to those previously described in conventional
mice (13, 14).
The administration poly(I:C) to CLP-treated control mice
significantly increased the values of lung damage markers
with no differences respect to ELP control animals. It was
also observed that in infant mice treated with CLP, the
administration of L. rhamnosus CRL1505 was not able
to reduce the levels of BAL LDH and albumin after the
challenge with poly(I:C) (Figure 1). Mice treated with
ELP or CLP and L. plantarum CRL1506 showed lung
injury markers values that were not different from their
respective controls (Figure 1).
The levels of IFN-β, IFN-γ, and IL-10 in BAL were also
determined after administration of poly(I:C), in infant mice
treated with CLP or ELP (Figure 1). The administration of the
TLR3 agonist induced significant increases in the levels of BAL
IFN-β, IFN-γ, and IL-10 in the ELP control mice, which were
similar to those previously reported (13, 14). It was also observed
that L. rhamnosus CRL1505 induced significant increases in the
levels of BAL IFN-β and IFN-γ as well as in IL-10 after the
administration of poly(I:C) in ELP-treated mice compared with
ELP controls (Figure 1).
In control infant mice treated with CLP, the values of the
three cytokines were similar to the found in the ELP control
group after the stimulation with poly(I:C). The treatment of
CLP mice with L. rhamnosus CRL1505 increased the levels
of IFN-γ, but the values of this cytokine did not reach the
levels observed in mice treated with ELP and the CRL505
strain (Figure 1). It was also observed that in infant mice
treated with CLP, the administration of L. rhamnosus CRL1505
was not able to increase the levels of BAL IFN-β or IL-
10 after the challenge with poly(I:C) when compared to
FIGURE 2 | Effect of alveolar macrophages depletion on the ability of Lacticaseibacillus rhamnosus CRL1505 to modulate the respiratory immune response triggered
by Respiratory Syncytial Virus (RSV) infection. Infant mice were nasally treated with clodronate-containing liposomes (CLP) during 2 days (days 0 and 1) to induce the
depletion of alveolar macrophages. One day after the last CPL administration mice were orally treated with L. rhamnosus CRL1505 or Lactiplantibacillus plantarum
CRL1506 (108 cell/mouse/day) during five consecutive days (days 2–6) and then challenged with RSV (day 8). Mice treated with empty liposomes (ELP), CRL1505 or
CRL1506 and then challenged with poly(I:C) were used as controls. Two days after the viral challenge, lung RSV titers, lactate dehydrogenase (LDH) activity, albumin
concentrations, and the levels of interferon (IFN)-β, IFN-γ, and interleukin (IL)-10 in broncho-alveolar lavages (BAL) were evaluated. The results represent data from
three independent experiments. Asterisks indicate significant differences between the respective ELP and CLP groups. Asterisks in black lines indicate significant
differences between the indicated groups. *P < 0.05, **P < 0.01.
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the CLP control group (Figure 1). Again, mice treated with
ELP or CLP and L. plantarum CRL1506 showed respiratory
cytokines values that were not different from their respective
controls (Figure 1).
These results suggest that alveolar macrophages are a key
immune cell population involved in the differential cytokine
induction and in the protection against lung damage induced
by orally administered L. rhamnosus CRL1505 in the context of
TLR3-mediated inflammation.
Effect of Alveolar Macrophages Depletion
on the Capacity of L. rhamnosus CRL1505
to Modulate the RSV Infection
We further evaluated the impact of alveolar macrophages
depletion in the ability of L. rhamnosus CRL1505 to improve
the resistance against RSV infection. As shown in Figure 2,
infant mice treated with CLP had similar lung RSV titers than
the observed in ELP-treated mice. The L. rhamnosus CRL1505
treatment was able to reduce RSV titers in both ELP- and
CLP-treated infant mice. However, the lung viral titers in
CLP+CRL1505 mice were significantly higher than the found
in the ELP+CRL1505 group (Figure 2). It was also observed
that L. rhamnosus CRL1505 was able to significantly reduce
BAL albumin and LDH values in ELP-treated infant mice after
the infection with RSV (Figure 2). In CLP-treated mice, the
levels of BAL albumin and LDH were similar to the infant
mice in the ELP control group. L. rhamnosus CRL1505 was
not able to reduce the levels of BAL albumin or LDH in CLP-
treated infant mice when compared to the CLP control group
(Figure 2). Mice treated with ELP or CLP and L. plantarum
CRL1506 showed lung injury markers values that were not
different from their respective controls after the challenge with
RSV (Figure 2).
The levels of BAL IFN-β, IFN-γ, and IL-10 were also
determined after the RSV infection in infant mice treated
with liposomes (Figure 2). The viral challenge significantly
augmented the levels of BAL IFN-β, IFN-γ, and IL-10 in ELP-
treated and CLP-treated mice, with no differences between
the groups. Similar to our previous results (13), it was
observed that L. rhamnosus CRL1505 significantly augmented
the levels of BAL IFN-β, IFN-γ, and IL-10 after RSV challenge
of infant mice treated with ELP. The levels of both BAL
IFN-β and IFN-γ in mice treated with CLP+CRL1505 were
significantly lower than the found in the ELP+CRL1505 group
(Figure 2). However, BAL IFN-γ in the CLP+CRL1505 group
was significantly higher than CLP controls. In addition, it
was observed that in infant mice that received CLP, the
treatment with L. rhamnosus CRL1505 was unable to modify
BAL IL-10 values after RSV infection when compared to
the CLP control group (Figure 2). Mice treated with ELP
or CLP and L. plantarum CRL1506 showed respiratory
cytokines values that were not different from their respective
controls (Figure 2).
These RSV challenge experiments suggest that alveolar
macrophages are a key immune cell population involved in
the protection against virus-induced lung damage as well as in
the differential respiratory cytokine profile induced by orally
administered L. rhamnosus CRL1505.
Effect of L. rhamnosus CRL1505 on
Alveolar Macrophages Cytokine Profiles in
Response to Poly(I:C) or RSV
Taking into consideration that the previous results suggested
that the alveolar macrophages would have a relevant role
in the immunomodulatory effect of L. rhamnosus CRL1505,
the changes induced by the strain on alveolar macrophages
cytokine profile were then studied. For this purpose,
primary cultures of alveolar macrophages from control, L.
rhamnosus CRL1505- or L. plantarum CRL1506-treated
infant mice were performed and cells were challenged in
vitro with poly(I:C) (Figure 3), or RSV (Figure 4). Basal
production of IFN-β, IFN-γ, IL-6, IL-12 as well as the
immunoregulatory cytokines IL-10 and IL-27 was detected
in alveolar macrophages cultures. Moreover, the basal levels
of all the cytokines evaluated were significantly higher in
alveolar macrophages cultures obtained from L. rhamnosus
CRL1505-treated infant mice when compared to controls
(Figure 3). On the contrary, the levels of all the cytokines
evaluated in alveolar macrophages cultures obtained from L.
plantarum CRL1506-treated infant mice were not different from
controls (Figure 3).
The challenge with poly(I:C) (Figure 3) significantly increased
the levels of IFN-β, IFN-γ, IL-6, and IL-12 in control
alveolar macrophages cultures as well as in those obtained
from CRL1505- or CRL1506-treated infant mice. However, the
concentrations of IL-6, IFN-β, and IFN-γ were significantly
higher in alveolar macrophages cultures from L. rhamnosus
CRL1505-treated infant mice when compared to the control
group, while IL-12 was not different from control macrophages.
In addition, poly(I:C) challenge significantly increased the
levels of IL-10 and IL-27 in alveolar macrophages cultures.
However, the concentrations of IL-27 were significantly higher
in cultures from L. rhamnosus CRL1505-treated infant mice
when compared to the control group. No differences were
observed in IL-10 levels when control macrophages were
compared to those obtained from CRL1505-treated infant
mice (Figure 3). Similarly, the challenge with RSV significantly
increased IFN-β, IFN-γ, IL-6, IL-12, IL-10, and IL-27 in all
the experimental groups. However, the concentrations of IFN-
β, IFN-γ, IL-6, IL-12, and IL-27 were significantly higher in
alveolar macrophages cultures from L. rhamnosus CRL1505-
treated infant mice when compared to the control group.
No differences were observed in IL-10 levels when control
macrophages were compared to those obtained from CRL1505-
treated infant mice (Figure 4). The levels of all the cytokines
evaluated in alveolar macrophages cultures obtained from L.
plantarum CRL1506-treated infant mice were not different
from controls after poly(I:C) stimulation (Figure 3) or RSV
challenge (Figure 4).
These results indicate that the signals delivered by
orally administered L. rhamnosus CRL1505 to alveolar
macrophages are capable of modulating the cytokine
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FIGURE 3 | Effect of Lacticaseibacillus rhamnosus CRL1505 on alveolar macrophages cytokine profiles in response to poly(I:C) challenge. Infant mice were orally
treated with L. rhamnosus CRL1505 or Lactiplantibacillus plantarum CRL1506 (108 cell/mouse/day) during five consecutive days. One day after the last lactobacilli
administration, alveolar macrophages were isolated from infant mice, cultured, and challenged in vitro with poly(I:C). Twenty-four hours after the poly(I:C) stimulation,
the levels of interferon (IFN)-β, IFN-γ, interleukin (IL)-6, IL-10, IL-12, and IL-27 were evaluated on alveolar macrophages supernatants. The results represent data from
three independent experiments. Asterisks indicate significant differences between the basal and post-poly(I:C) challenge time points within each group. Asterisks in
black lines indicate significant differences between the indicated groups. *P < 0.05.
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FIGURE 4 | Effect of Lacticaseibacillus rhamnosus CRL1505 on alveolar macrophages cytokine profiles in response to Respiratory Syncytial Virus (RSV) infection.
Infant mice were orally treated with L. rhamnosus CRL1505 or Lactiplantibacillus plantarum CRL1506 (108 cell/mouse/day) during five consecutive days. One day
after the last lactobacilli administration, alveolar macrophages were isolated from infant mice, cultured and challenged in vitro with RSV. Twenty-four hours after the
viral infection, the levels of interferon (IFN)-β, IFN-γ, interleukin (IL)-6, IL-10, IL-12, and IL-27 were evaluated on alveolar macrophages supernatants. The results
represent data from three independent experiments. Asterisks indicate significant differences between the basal and post-RSV challenge time points within each
group. Asterisks in black lines indicate significant differences between the indicated groups. *P < 0.05.
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FIGURE 5 | Effect of Lacticaseibacillus rhamnosus CRL1505 on alveolar macrophages antiviral factors profiles in response to Respiratory Syncytial Virus (RSV)
infection. Infant mice were orally treated with L. rhamnosus CRL1505 or Lactiplantibacillus plantarum CRL1506 (108 cell/mouse/day) during five consecutive days.
One day after the last lactobacilli administration, alveolar macrophages were isolated from infant mice, cultured and challenged in vitro with RSV. Twelve hours after the
viral infection, the expression of IFN-α, IFN-β, IFN-γ , IFNAR1, IFN-λ1, IFN-λ2/3, Mx1, Mx2, OAS1, OAS2, RNAseL, and IFITM3 genes were evaluated by qRT-PCR.
The results represent data from three independent experiments. Asterisks indicate significant differences when compared to the control group. *P < 0.05, **P < 0.01.
response of these immune cells in front of RSV infection
and TLR3 activation.
Effect of L. rhamnosus CRL1505 on
Alveolar Macrophages Antiviral Factors
Expression in Response to RSV Infection
We further characterized the response of alveolar macrophages to
RSV challenge by studying the expression levels of IFN-α, IFN-
β, IFN-γ , IFNAR1, IFN-λ1, IFN-λ2/3, Mx1, Mx2, OAS1, OAS2,
RNAseL, and IFITM3 genes. Primary cultures from alveolar
macrophages from control and lactobacilli-treated mice were
stimulated with RSV (Figure 5). As expected, the expressions
of IFN-α, IFN-β, and IFN-γ in alveolar macrophages from L.
rhamnosus CRL1505-treated mice were significantly higher than
the observed in macrophages from controls or mice treated with
L. plantarum CRL1506. In accordance with the improved type
I IFNs response, the levels of most of the ISGs in macrophages
from the CRL1505 group were significantly higher than the
control and the CRL1506 groups including IFNAR1, Mx2, OAS1,
OAS2, RNAseL, and IFITM3 (Figure 5). The only exception was
Mx1, which expression levels were similar in all the experimental
groups. In addition, no differences were found between control
and lactobacilli-treated mice when the expression of IFN-λ1
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FIGURE 6 | Effect of Lacticaseibacillus rhamnosus CRL1505 on broncho-alveolar lavages (BAL) leucocytes variations and CXCL1 and IL-17 levels in response to
Respiratory Syncytial Virus (RSV) infection. Infant mice were orally treated with L. rhamnosus CRL1505 or Lactiplantibacillus plantarum CRL1506 (108 cell/mouse/day)
during five consecutive days. One day after the last lactobacilli administration, mice were challenged with RSV. The numbers of BAL leucocytes, neutrophils,
lymphocytes, and macrophages/monocytes were evaluated before (basal) and 2 days after the RSV infection. The levels of BAL CXCL1 and IL-17 were measured 2
days after RSV challenge. The results represent data from three independent experiments. Asterisks indicate significant differences when compared to the control
group. *P < 0.05.
and IFN-λ2/3 were compared. These results indicate that the
signals delivered by orally administered L. rhamnosus CRL1505
to alveolar macrophages not onlymodulate the cytokine response
of these immune cells in front of RSV infection but also in
addition increase their antiviral state.
Induction of Activated Alveolar
Macrophages by L. rhamnosus CRL1505
We next aimed to evaluate the influence of the CRL1505 strain
on the numbers and activation of immune cell populations
in BAL before and after RSV infection. Alveolar macrophages
are the main cell population in BAL samples of non-infected
mice while lymphocytes are a minor population and neutrophils
are not detected (Figure 6). L. rhamnosus CRL1505 or L.
plantarum CRL1506 treatments did not modify the numbers
of BAL leucocytes in the steady state. The challenge with
RSV significantly increased the numbers of all BAL immune
cell populations in the three experimental groups. However,
CRL1505-treated mice had significantly lower numbers of total
leukocytes as well as neutrophils counts when compared to
controls (Figure 6). In line with this finding, the levels of CXCL1
in BAL samples from CRL1505-treated mice were significantly
lower than controls after RSV infection. Of note, BAL IL-17 levels
were not different when control and CRL1505-treated animals
were compared (Figure 6). L. plantarum CRL1506 treatment
was not able to modify the levels of BAL leukocytes or the
concentrations of CXCL1 or IL-17 after the challenge with RSV
with respect to the control group.
We further characterized the variations of resident
alveolar macrophages in BAL samples by flow cytometry.
Total resident alveolar macrophages population in BAL
(CD45+CD11c+SiglecF+ cells) were evaluated 1 day after
lactobacilli treatments, and 2 days after the infection with RSV
(Figure 7). The total numbers of alveolar macrophages were
not modified by lactobacilli treatments in the steady state. The
numbers of CD45+CD11c+SiglecF+ cell slightly increased upon
the challenge with RSV (Figure 7) indicating that the increase of
total numbers of BAL monocytes/macrophages (Figure 6) were
mainly produced by recruited cells. No differences were found
in CD45+CD11c+SiglecF+ cells between lactobacilli-treated
and control mice (Figure 7). The CD11c+SiglecF+MHC-IIhi
alveolar macrophages population was also evaluated in BAL
samples. In control mice, CD11c+SiglecF+MHC-IIhi cells
represented around the 25% of the total resident alveolar
macrophages population, being most alveolar macrophages
Frontiers in Immunology | www.frontiersin.org 11 September 2020 | Volume 11 | Article 568636
Garcia-Castillo et al. Modulation of Alveolar Macrophages by Immunobiotics
FIGURE 7 | Effect of Lacticaseibacillus rhamnosus CRL1505 on resident alveolar macrophages number and activation in response to Respiratory Syncytial Virus
(RSV) infection. Infant mice were orally treated with L. rhamnosus CRL1505 or Lactiplantibacillus plantarum CRL1506 (108 cell/mouse/day) during five consecutive
days. One day after the last lactobacilli administration, mice were challenged with RSV. Total resident alveolar macrophages populations in broncho-alveolar lavages
(BAL) (CD45+CD11c+SiglecF+ cells) as well as their expression of MHC-II were evaluated before (basal) and 2 days after the RSV infection. The results represent data
from three independent experiments. Asterisks indicate significant differences when compared to the control group. *P < 0.05.
MHC-IIlo cells. The number of CD11c+SiglecF+MHC-
IIhi cells significantly increased after the RSV infection
(Figure 7). The treatment with L. rhamnosus CRL1505 did not
induced statistical significant modifications in the numbers of
CD11c+SiglecF+MHC-IIhi cells at basal time, although the MFI
of MHC-II expression in alveolar macrophages of this group
of mice was higher than controls (Figure 7). In addition, the
numbers of CD11c+SiglecF+MHC-IIhi cells in L. rhamnosus
CRL1505-treated mice were higher than controls after the
RSV infection while CD11c+SiglecF+MHC-IIlo cells were
reduced (Figure 7). MHC-IIhi and MHC-IIlo resident alveolar
macrophages in mice treated with L. plantarum CRL1506 were
not different from controls in the two time points evaluated
(Figure 7). Then, these results allow us to speculate that the L.
rhamnosus CRL1505 treatment would be able to differentially
regulate the recruitment of immune cells into the respiratory
tract in response to RSV infection by modulating the activation
of alveolar macrophages.
Role of CD4 Cells and IFN-γ in the
Modulation of Alveolar Macrophages by L.
rhamnosus CRL1505
Previously, we demonstrated that the use of anti-IFN-γ blocking
antibodies abolish the ability of the CRL1505 strain to reduce
RSV titers in infected infant mice. In addition, the blocking of
IFN-γ partially affected the reduction of the lung inflammatory
damage during the course of RSV infection induced by
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FIGURE 8 | Effect of interferon (IFN)-γ depletion on the ability of Lacticaseibacillus rhamnosus CRL1505 to modulate the respiratory immune response triggered by
Respiratory Syncytial Virus (RSV) infection. Infant mice were orally treated with L. rhamnosus CRL1505 (108 cell/mouse/day) during five consecutive days. On days 1,
3, and 5 mice were injected intraperitoneally with purified anti-IFN-γ blocking antibodies or isotype control antibodies. One day after the last lactobacilli administration,
alveolar macrophages were isolated from infant mice, cultured, and challenged in vitro with RSV. Twelve hours after the viral infection, the expression of IFNAR1, Mx2,
OAS1, and IFITM3 genes were evaluated by qRT-PCR. Twenty-four hours after the viral infection, the levels of interferon IFN-β, IFN-γ, interleukin (IL)-6, and IL-27 were
evaluated on alveolar macrophages supernatants. The results represent data from three independent experiments. Asterisks indicate significant differences when
compared to the isotype control group. *P < 0.05, **P < 0.01.
orally administered L. rhamnosus CRL1505 (13). Then, we
aimed to evaluate whether IFN-γ was related to the effect of
the immunobiotic strain on alveolar macrophages. For this
purpose, anti-IFN-γ blocking antibodies were administered to
mice during the oral treatment with L. rhamnosus CRL1505.
Primary cultures from alveolar macrophages obtained from
these mice and isotype-treated control animals were prepared
and stimulated in vitro with RSV (Figure 8). The production
of IFN-β was significantly lower in alveolar macrophages
isolated from anti-IFN-γ blocking antibodies-treated mice
when compared to isotype controls. Consistently with this
finding, it was observed a significant reduction in the
expression of IFNAR1, Mx2, OAS1, and IFITM3 genes in
alveolar macrophages from anti-IFN-γ blocking antibodies-
treated mice than in isotype controls (Figure 8). In addition,
a significant reduction of IFN-γ, IL-6, and IL-27 production
was observed in alveolar macrophages of mice depleted
from IFN-γ during L. rhamnosus CRL1505 administration
(Figure 8).
In another set of experiments, anti-CD4 blocking antibodies
were administered to mice during the oral treatment with
L. rhamnosus CRL1505. The response of primary cultures
of alveolar macrophages of this group of mice to RSV
challenge was also evaluated (Figure 9). Similar to IFN-γ
blocking experiments, the depletion of CD4 cells during L.
rhamnosus CRL1505 administration significantly reduced
the capacity of alveolar macrophages to produce IFN-β,
IFN-γ, IL-6, and IL-27 or express IFNAR1, Mx2, OAS1,
and IFITM3 genes in response to RSV challenge (Figure 9).
Interestingly, anti-CD4 blocking antibodies induced a
significantly higher reduction of IFN-β, IFN-γ, and ISGs than
anti-IFN-γ blocking antibodies.
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FIGURE 9 | Effect of CD4T cells depletion on the ability of Lacticaseibacillus rhamnosus CRL1505 to modulate the respiratory immune response triggered by
Respiratory Syncytial Virus (RSV) infection. Infant mice were orally treated with L. rhamnosus CRL1505 (108 cell/mouse/day) during five consecutive days. On days 1,
3, and 5 mice were injected intraperitoneally with purified anti-CD4 blocking antibodies or isotype control antibodies. One day after the last lactobacilli administration,
alveolar macrophages were isolated from infant mice, cultured, and challenged in vitro with RSV. Twelve hours after the viral infection, the expression of IFNAR1, Mx2,
OAS1, and IFITM3 genes were evaluated by qRT-PCR. Twenty-four hours after the viral infection, the levels of interferon IFN-β, IFN-γ, interleukin (IL)-6, and IL-27 were
evaluated on alveolar macrophages supernatants. The results represent data from three independent experiments. Asterisks indicate significant differences when
compared to the isotype control group. *P < 0.05, **P < 0.01.
These results highlight the role of IFN-γ and CD4 cells in the
modulation of alveolar macrophages activation induced by orally
administered L. rhamnosus CRL1505.
DISCUSSION
Studies reported an important role for intestinal microbiota
in maintaining respiratory antiviral immunity through the
modulation of the immune response both at the steady state as
well as in response to the viral attack (1–3). Remarkably, research
work showed a significant impact of the intestinal microbiota
in the respiratory innate antiviral defense mechanisms thought
its influence on antigen presenting cells. The studies of Abt
et al. (2) demonstrated that the intestinal microbiota help to
maintain the optimal functions of pulmonary macrophages. The
intestinal microbiota is involved in the efficient capacity of
pulmonary macrophages to produce type I IFNs, IFN-λ and
antiviral factors including Irf7, Ifngr1, Stat1, Stat2, Mda-5, Rig-
I, Ifit3, Mx1, and Oas1 to limit IFV replication (2). In line
with these findings, some studies reported the ability of orally
administered immunobiotic strains to regulate the function of
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macrophages in the respiratory tract. It was shown that the oral
treatment of adult mice with L. gasseri A5 differentially regulated
the cytokine profile of alveolar macrophages by increasing their
production of IL-12 and decreasing IL-17 and IL-23 (23). The
oral administration of a complex mixture of probiotic strains,
which included L. rhamnosus GG and E. coli Nissle 1917 among
others, was able to modify the composition of the intestinal
microbiota and their metabolic profiles inducing an augmented
production of short chain fat acids. These metabolic products
influenced alveolar macrophages’ function by up-regulating
their expression of IFN-β and antiviral factors, increasing the
resistance of adult mice to RSV infection (24). In addition,
feeding of adult mice with L. gasseri SBT2055 improved the
expression of Mx1 and Oas1 in alveolar macrophages and
diminished the susceptibility to IFV infection (25). An enhanced
resistance to IFV challenge was also observed in adult mice orally
treated with L. plantarum DK119. Interestingly, the depletion
of alveolar macrophages completely abolished the capacity
of the DK119 strain to protect mice against the respiratory
viral infection (26).
In line with those studies, we previously reported that
orally administered L. rhamnosus CRL1505 was capable to
modulate alveolar macrophages function in adult mice (27). The
CRL1505 strain increased the phagocytic and microbicidal
activity of alveolar macrophages, and improved their
production of IFN-γ and TNF-α in response to Streptococcus
pneumoniae challenge. In addition, increased numbers of
CD11c+SiglecF+IFN-β+ alveolar macrophages were found
in mice preventively treated with L. rhamnosus CRL1505 and
then challenged with poly(I:C) or RSV (13, 14). In this work,
we have extended those previous findings by consistently
demonstrating a relevant role of alveolar macrophages in
the immunomodulatory capacity of orally administered L.
rhamnosus CRL1505 in the context of RSV infection in infant
mice. Macrophages depletion experiments and a detailed study
of their production of cytokines and antiviral factors clearly
demonstrated the key role of this immune cell population
in the improvement of both viral elimination and protection
against lung tissue damage induced by the immunobiotic
CRL1505 strain.
The phagocytic activity of alveolar macrophages is crucial
for the elimination of infected cells during the course of
respiratory virus infection. In addition, it was reported that
alveolar macrophages play a prominent role in the defense
against respiratory viruses such as RSV by producing type
I IFNs (28). Moreover, some studies suggested that alveolar
macrophages are the most important producers of IFN-α/β
in response to RSV challenge, even when compared to other
respiratory cells such as epithelial cells and plasmacytoid DCs
(29, 30). Type I IFNs produced by alveolar macrophages can
act on this same cell population or on other immune and
non-immune cells of the respiratory tract modulating their
expression of hundreds of ISGs that contribute to viral clearance
(31). Type I IFNs production by alveolar macrophages also
induce the expression of several monocyte chemoattractants
in the respiratory tract that induce the recruitment of
CD11cloCD64hiCD11b+ inflammatory monocytes/macrophages
that further support the clearance of virus-infected cells (29).
On the other hand, it was reported that RSV is capable
of infecting both human and murine alveolar macrophages
although the infection is abortive since there is no increment
of viral particle production (18, 32). However, RSV induce a
significant impairment in the production of IFN-γ and IL-
12 by alveolar macrophages (33) that was associated with an
enhanced severe illness in infants (34). The reduced levels of
IFN-γ diminish alveolar macrophages activation, impairing their
phagocytic function and their ability to induce the recruitment
of T and NK cells to the lungs, contributing to higher viral
replication (35, 36). Then, the efficient and timely production of
type I IFNs, ISGs and IFN-γ is important to confer protection
against RSV.
We previously reported enhanced levels of IFN-β and
IFN-γ in BAL samples of CRL1505-treated mice after TLR3
activation (13), RSV challenge (14) or IFV infection (37).
The results of this work clearly demonstrated the ability of
orally administered L. rhamnosus CRL1505 to enhance the
ability of alveolar macrophages to produce type I IFNs, ISGs
and IFN-γ in response to RSV infection. Our results indicate
that alveolar macrophages greatly contribute to the augment
of IFN-β and IFN-γ in the respiratory tract of CRL1505-
treated mice. Moreover, we reported here for the first time an
improved expression of IFNAR1, Mx2, OAS1, OAS2, RNAseL,
and IFITM3 in alveolar macrophages after the oral treatment
with L. rhamnosus CRL1505. OAS1 is capable of inhibiting
protein synthesis and viral growth by degrading viral and
cellular RNA while IFITM3 has the ability to block early
events in the viral replication cycle. Both, OAS1 and IFTIM3
have been shown to interfere with RSV replication and limit
productive infection (31, 38). The members of OAS family
are able to activate RNAseL, being AOS2 more efficient that
OAS1 to induce this effect. The intracellular endoribonuclease
RNaseL activated by OAS molecules cleaves viral and cellular
RNA resulting in apoptosis (39). It was shown that IFN-γ is
able to up-regulate the activities of OAS/RNAseL increasing
the protection against RSV infection (40). In addition, recent
studies in cotton rats demonstrated differences in RSV infection
severity related to the age. While adult animals were resistant
to RSV infection, infant rats were highly susceptible to the
viral infection. Interestingly, the work reported that the higher
viral load and lung pathology observed in younger animals was
related to a lower ability to up-regulate IFN-α/Mx2 levels in the
respiratory tract (41). The enhancement of these antiviral factors
is consistent with the improved clearance of RSV (14) and IFV
(37) induced by the oral treatment with the immunobiotic strain.
Furthermore, the identification of the differential antiviral factors
and cytokines profiles induced by L. rhamnosus CRL1505 in
alveolar macrophages indicate that the immunobiotic treatment
has the potential to protect against other respiratory viruses
as well.
The role of alveolar macrophages in the protective immune
responses against RSV have been demonstrated in some animal
models in which this immune cell population was specifically
depleted. Experiments in adult mice demonstrated that the
depletion of alveolar macrophages by the administration of
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clodronate liposomes before the challenge with RSV significantly
impaired the production of IFN-α, TNF-α, and IL-6 in the
respiratory tract and diminished the activation and recruitment
of NK cells. Those changes were associated to an enhanced
lung RSV load (42). Experiments in CD169-diphtheria toxin
receptor transgenic mice, which are depleted from CD169+
alveolar macrophages after the administration diphtheria
toxin, also demonstrated that macrophages elimination
impaired the production of IFN-β, IL-6, and TNF-α in the
respiratory tract in response to RSV infection (43). By using a
similar approach, we demonstrated here that the depletion of
alveolar macrophages by the time of L. rhamnosus CRL1505
administration abolished the ability of infant mice to produce
improved levels of IFN-β in response to TLR3 activation
or RSV infection. In addition, although the production of
IFN-γ was diminished when alveolar macrophages were
depleted; the levels of this cytokine were still significantly
higher in CRL1505-treated mice than in controls. These results
indicate that other immune cell population also contribute
to the improved levels of IFN-γ in the respiratory tract of
CRL1505-treated mice. The most likely source of IFN-γ are
CD4+ T cells as discussed below. Of note, the depletion of
alveolar macrophages completely abolished the ability of orally
administered L. rhamnosus CRL1505 to improve IL-10 in the
respiratory tract or to reduce the biochemical markers of lung
injury after TLR3 activation or RSV infection. Then, alveolar
macrophages had a key role in the protection against the
lung detrimental inflammation induced by the immunobiotic
CRL1505 strain.
The alteration of alveolar macrophages function by the
infection with RSV has been associated to an exacerbated viral-
mediated bronchiolitis (35). In fact, the depletion of alveolar
macrophages greatly increased the recruitment of inflammatory
cells to the lung during the early stage of RSV infection.
The depletion of alveolar macrophages induce a significant
greater lung inflammation in response to RSV challenge that
is characterized by increases in CD11bhiGr1hi neutrophils and
inflammatory CD11chiMHC-IIhiCD11b+ DCs that contribute
to an hyperresponsiveness in RSV-infected mice (18). Notably,
this deregulated inflammatory response contribute poorly to
the elimination of the virus while promoting local damage
and affecting lung function. Then, the immunoregulatory
functions of alveolar macrophages seems crucial for avoiding
the lung inflammatory-mediated damage during the course of
RSV infection. Several mechanisms have been proposed for
the immunoregulatory functions of alveolar macrophages in
the context of viral infections. The most obvious function of
macrophages is the phagocytosis of virus-infected apoptotic cells
preventing the release of cellular contents to local environment
and avoiding the triggering of further inflammatory factors
production (44). It was also shown that alveolar macrophages
produce anti-inflammatory cytokines such as IL-10, especially
during the resolution of the infection (32, 44). Another anti-
inflammatory strategy of alveolar macrophages is their ability to
promote Treg cells responses by directly interacting with these
cells or indirectly through the production of certain cytokines
(45, 46). It was reported that resident CD11c+SiglecF+ alveolar
macrophages pulsed in vitro with ovalbumin are able to induce
the development of Foxp3+ Treg cells when they are co-cultured
with antigen-specific CD4T cells (45). Moreover, the transfer
of the ovalbumin-pulsed macrophages into the respiratory tract
of mice significantly reduced the lung inflammation upon
subsequent stimulation with the antigen. On the other hand,
it was demonstrated that IL-6 is required for the reduction of
RSV-induced immunopathology. The early production of IL-
6 after RSV challenge stimulates the expression of IL-27 by
alveolar macrophages, which in turn promotes the maturation
of Treg cells in the respiratory tract (46). Our previous studies
(13, 14, 37) and the results presented here allow us to conclude
that some of these anti-inflammatory functions of alveolar
macrophages are enhanced by the oral administration of L.
rhamnosus CRL1505.
We have reported increased levels of IL-10 in the respiratory
tract of L. rhamnosus CRL1505-treated mice and partially
attributed this increment to the enhanced production of this
immunoregulatory cytokine by alveolar macrophages (13, 14,
27). The data of this work show that this assertion was incorrect,
since the study of the production of IL-10 by the alveolar
macrophages in CRL1505-treated infant mice were not different
from controls at the basal level or upon stimulation with
poly(I:C) or RSV. On the other hand, we demonstrated here
for the first time that alveolar macrophages from L. rhamnosus
CRL1505-treated mice had a significantly increased capacity
to produce IL-27 in response to TRL3 activation or RSV
stimulation. The immunoregulatory cytokine IL-27 have been
shown to modulate inflammatory responses by acting in cells
from both innate and adaptive immunity (47). Recent studies
highlighted the role of IL-27 in the protection against lung
inflammatory damage during the course of viral infections. It
was reported that IL-27RA−/− mice have an exaggerated lung
immunopathology after the infection with IFV, that correlated
with increased levels of CD4+ and CD8+ T cells producing
IL-17 and a strong neutrophil infiltration (48). In addition,
the depletion of IL-27 in the respiratory tract during RSV
infection enhanced the damaging inflammation (46). It was
also shown that IL-27 helps in the control of RSV infection
severity by suppressing Th17- and Th2-mediated inflammation
(49). Interestingly, comparative studies of IFV infection in IL-
27RA−/− and IL-10−/− mice demonstrated that the former had
a more severe disease course than the latter (48), demonstrating
that not all the anti-inflammatory effects of IL-27 are mediated
by the induction of IL-10 production as it has been suggested
(47, 50, 51). Of note, it was reported that IL-27 is not
sufficient for the optimal induction of Treg cells maturation
in the respiratory tract and that IL-6 is required for the IL-
27/Treg cells protection against inflammatory damage. The early
production of IL-6 after RSV infection induce the production of
IL-27 by myeloid cells including alveolar macrophages, which
in turn stimulates Treg cell maturation. Depletion of IL-27
or IL-6 in the respiratory tract during RSV have the same
detrimental effect on the maturation of Treg cells and RSV-
mediated immunopathology (46). Then, our results show that the
improved production of IL-27 and IL-6 by alveolar macrophages
of CRL1505-treated mice may play an important role in
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limiting inflammation and protecting lung function during
RSV infection, by increasing the maturation and activation of
Treg cells.
Macrophage’s functions have been studied in the context
the M1/M2 polarization dichotomy being classically activated
macrophages (M1-like) associated to pro-inflammatory
microenvironments while alternatively activated macrophages
(M2-like) developed in anti-inflammatory environments (52).
M1-like macrophages are characterized by a high phagocytic
activity and by their ability to guide acute inflammatory
responses through their production of pro-inflammatory
factors that stimulate the Th1 response. On the other hand,
M2-like macrophages negatively regulate pro-inflammatory
cytokines, and induce the production of anti-inflammatory
mediators contributing to the control of inflammation, tissue
repair and the return to hemostasis of the infected tissue (52).
However, recent advances in the biology of macrophages have
demonstrated that this dichotomy separating M1-like and
M2-like macrophages is rather represented by a continuum
between the two states. This fact is particularly true for alveolar
macrophages that have been shown to express a combined
M1/M2 phenotype (53). It was suggested that this hybrid
phenotype confer to alveolar macrophages the ability to quickly
switch between M1 or M2 associated functions allowing for
appropriate responses to stimuli and tissue environment.
During the acute phase of inflammation, alveolar macrophages
may function as M1 activated cells inducing the activation of
various mechanisms that contribute to pathogen elimination.
However, such responses must be controlled to prevent lung
tissue damage through the activation of M2 functions that
control inflammatory reactions, and promote and accelerate
the wound healing process and tissue repair. Such a fine-tuned
balance and switching back and forth between the M1 and
M2 polarization states in alveolar macrophages would be
necessary to allow the beneficial processes of inflammation,
resolution, and repair (52, 53). Then, it could be concluded
that the oral treatment with L. rhamnosus CRL1505 would not
induce differential modifications of alveolar macrophages but
instead it would stimulate and improve a function that is already
programmed in this particular population of immune cells of the
respiratory tract.
As mentioned before, studies demonstrated that alveolar
macrophages have a great impact in the innate antiviral immune
response to RSV. However, their role in the generation of
adaptive immune responses has not been completely elucidated.
It was shown the macrophage depletion did not affect the
recruitment of activated CD4+ T cells into the lung, indicating
that this immune cell population may have little effect on
the adaptive response to RSV (42). In contrast, the depletion
of alveolar macrophages before the nasal immunization with
an experimental RSV vaccine based on the viral G protein
significantly reduced the levels of specific neutralizing antibodies
(54). Mice with depleted alveolar macrophages had an impaired
protection against RSV challenge when compared to normal
controls. In addition, the depletion of CD169+ alveolar
macrophages reduced the recruitment of effector CD8+ T cells
to the lungs after RSV infection (43). On the other hand,
it was reported that the influence of intestinal microbiota
on the respiratory innate antiviral immune response is able
to condition the subsequent adaptive immune responses. The
intestinal microbiota was shown to positively influence the
ability of pulmonary macrophages to support the generation
of virus-specific antibodies as well as virus-specific T cells.
In intestinal microbiota-depleted mice, macrophages had a
reduced expression of MHC-I and CD86 molecules. An impaired
number of IFV-specific CD8+ T cells as well as a reduced
ability of these cells to produce IFN-γ, TNF-α, IL-2, and
MIP-1α was also observed (2). Taking into consideration the
findings of this work demonstrating that orally administered L.
rhamnosus CRL1505 influence the MHC-II expression of the
alveolar macrophages during the course of RSV infection, it
is tempting to speculate that the immunobiotic intervention
would also beneficially modify the adaptive immune response
against the viral pathogen in infant mice. In support of this
hypothesis, it has been shown that IFN-γ is able to up-
regulate MHC-II expression in alveolar macrophages improving
their antigen presentation activities (55). The evaluation of the
influence of L. rhamnosus CRL1505 in the adaptive immune
response to RSV and the role of alveolar macrophages in
this potential beneficial effect is an interesting topic for
future research.
In addition, we provided evidence that support an important
role of CD4+ cells and IFN-γ in the ability of L. rhamnosus
CRL1505 to modulate alveolar macrophages activities and the
subsequent improved response to RSV infection. In our hands,
the administration of anti-IFN-γ or anti-CD4 antibodies at
the time of the CRL1505 treatment completely abolished the
ability of the immunobiotic strain to differentially modulate the
cytokine and antiviral factors profile of alveolar macrophages.
The inefficient production of IFN-γ in the respiratory tract
during the course of RSV infection with the subsequent impaired
activation of alveolar macrophages has been associated with
an increase of severe bronchiolitis and pneumonia in neonates
and infants (34–36). In addition, comparative studies of RSV
challenge in infant and adult mice demonstrated that in IFN-
γ production were associated to the distinct susceptibility of
both groups to viral infection (36, 55). Adult mice are able
to induce the recruitment of CD8+IFN-γ+ and CD4+IFN-γ+
T cells in the lung, which activated alveolar macrophages and
promoted an efficient viral clearance. In contrast, infant mice
were capable of inducing the recruitment of CD8+IFN-γ+ T
cells in the respiratory tract. The lack of effective recruitment
of CD4+IFN-γ+ T cells into the alveolar space and the lower
activation of macrophages correlated with the higher RSV loads
in the lungs of infant mice. These previous findings and the
results of this work highlight the role of CD4+ cells and
IFN-γ in the activation of alveolar macrophages induced by
L. rhamnosus CRL1505 and in the modulation of respiratory
antiviral immunity.
The exact origin and nature of the signals used by the intestinal
microbiota or orally administered immunobiotics to modulate
the respiratory antiviral immunity remain to be determined.
Our experiments blocking CD4+ cells and IFN-γ allow us to
hypothesize about a potential mechanism that could explain
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the remote effect induced by orally administered L. rhamnosus
CRL1505. The existence of the so-called common mucosal
immune system implies that the immune cells activated in
one mucosal tissue can mobilize and reach distant mucosal
sites where they can influence immune responses. Then, the
mobilization of B and T cells from the intestinal mucosa
to the respiratory tract could be involved in the beneficial
effects exerted by the intestinal microbiota or immunobiotics
(6, 56). It was also hypothesized that immune factors such
as cytokines and growth factors produced in the intestinal
mucosa in response to microbiota stimulation, can be released
to blood and act systemically or in other mucosal tissues (56,
57). We previously demonstrated that both orally administered
L. rhamnosus CRL1505 and L. plantarum CRL1506 were
capable of improving the levels of IFN-γ in the intestine
and blood, while only the CRL1505 strain increased this
immune factor in the respiratory tract, indicating that the
IFN-γ was produced locally (13). In addition, our previous
results indicated that the oral administration of L. rhamnosus
CRL1505 induces an increase of CD4+IFN-γ+ T cells in the
lungs, and effect that was not observed in CRL1506-treated
mice (14). Then, considering those previous results and the
ones obtained in this work it is tempting to speculate that L.
rhamnosus CRL1505 would induce the mobilization CD4+IFN-
γ+ T cells from the intestine to the lungs, and that the
IFN-γ produced by mobilized CD4+ T cells would modulate
the respiratory tract innate immune microenvironment leading
to the activation of local immune cells such as alveolar
macrophages. Conducting more in-depth studies to verify this
hypothesis is a task that we intend to carry out in the
immediate future.
Of note, other probable mechanisms have been proposed,
which are not mutually exclusive, to explain the effect of
the intestinal beneficial microbes on the respiratory antiviral
immunity. There is evidence that some microbial-associated
molecular patterns (MAMPs) derived from the intestinal
microbiota can be adsorbed and transported to extraintestinal
sites where they stimulate pattern recognition receptors (PRRs)
expressed in non-immune and immune cells influencing
the immune responses (58, 59). In addition, microbial
metabolites that are adsorbed in the intestine have been
associated to the differential modulation of respiratory
immune responses. This effect has been called “metabolic
reprograming” (60) and implies that metabolites such as
circulating short-chain fatty acids (61), desaminotyrosine
(5), docosahexanoic acid (62), or acetate (4) can reach
innate immune cells in the respiratory tract and improve
their responses to viral infections. Studying whether these
mechanisms contribute to the immunomodulatory effect
of L. rhamnosus CRL1505 is also an interesting topic for
future research.
Alveolar macrophages are a crucial component of innate
host defense in the respiratory tract and this immune cell
population have been demonstrated to play a critical role
limiting the severity of RSV-induced disease. In this study,
we defined the importance of alveolar macrophages as
a key players in the immunomodulatory and protective
activities of orally administered L. rhamnosus CRL1505
in the context of RSV infection in infants. In addition,
we provided evidence of the important role of CD4+
cells and IFN-γ in the activation of alveolar macrophages
highlighting a putative pathway through which the intestinal and
respiratory mucosa are communicated under the influence of L.
rhamnosus CRL1505.
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